Hogg R S, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens[J]. Can Med Assoc J,1999,160(5):659.
[4]
Law M G, Friis-Moller N, El-Sadr W M, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study[J]. HIV Med,2006,7(4):218.
[5]
Dubé M P, Stein J H, Aberg J A, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV medical association of the infectious disease society of America and the adult AIDS clinical trials group[J]. Clin Infect Dis,2003,37(5):613.
[6]
Lundgren J D, Battegay M, Behrens G, et al. European AIDS clinical society (EACS) guidelines on the prevention and management of metabolic diseases in HIV[J]. HIV Med,2008,9(2):72.
[7]
Mallewa J E, Wilkins E, Vilar J. et al.HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options[J].J Antimicrob Chemother, 2008,62(4):648.
[8]
Lucas G M, Chaisson R E, Moore R D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions[J].Ann Intern Med,1999,131(2):81.
[9]
Friis-Moller N, Weber R, D\'Arminio Monforte A, et al. Exposure to HAART is associated with an increased risk of myocardial infarction: the DAD study [C]. Boston: 10th Conference on Retroviruses and Opportunistic Infections, 2003.
[10]
Bozzette S A, Ake C, Carpenter A, et al.Cardio and cerebrovascular outcomes with changing process of anti-HIV therapy in 36,766 US veterans [C]. Washington: 9th Conference on Retroviruses and Opportunistic Infections, 2002.
[11]
Lee E C, Walmsley S, Fantus I G. New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review[J]. Can Med Assoc J, 1999,161(2):161.
[12]
Carr A, Samaras K, Chisholm D J, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance[J].Lancet,1998,351(9119):1881.
Zhao S P,Liu L,Cheng Y C,et al.Effect of xuezhikang,a cholestin extract,on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease[J]. Atherosclerosis,2003,168(2):375.
Liu L,Zhao S P,Cheng Y C,et al.Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease[J].Clin Chem,2003,49(8):1347.
[21]
Zhao S P,Liu L,Cheng Y C,et al.Effect of xuezhikang,a cholestin extract,on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease[J]. Atherosclerosis,2003,168(2):375.
[22]
Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS cohort study investigators[J].J Am Med Assoc,1998,280(17):1497.
[23]
Cicconi P, Cozzi-Lepri A, Castagna A, et al.Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients[J]. HIV Med, 2010,11(2):104.
[24]
Lucas G M, Chaisson R E, Moore R D. Highly active antiretroviral therapy in a large urban clinic, risk factors for virologic failure and adverse drug reactions[J].Ann Intern Med,1999,131(2):81.
[25]
Chen D, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients[J]. J Clin Endocrinol Metab,2002,87(11): 4845.
[26]
Kinlaw W B, Marsh B. Adiponectin and HIV-lipodystrophy: taking HAART[J]. Endocrinol,2004,145(2): 484.
